文献速递慢病管理预防保健、筛查与疫苗

社会处方在2型糖尿病预防中的公平性与效果:基于国家初级保健数据的横断面与队列研究

Equity and impact of social prescribing in type 2 diabetes prevention: cross-sectional and cohort study using national primary care data.
PubMed 文献 · Br J Gen Pract · 2026-10-19

该研究利用英格兰超过1800家全科诊所的常规数据,分析社会处方在高危2型糖尿病成人中的可及公平性与预防效果。结果显示社会处方覆盖了健康与社会需求更高的人群,且随服务成熟和随访延长,社会处方与T2D风险降低相关。

要点

  • 社会处方转诊在高危T2D成人中从2019-2020年的0.3%增至2023年的2.5%,增长9.5倍。
  • 女性、贫困地区居民、吸烟者、肥胖者、抑郁/焦虑及多病患者更常被转诊社会处方。
  • 社会处方与T2D风险的关联随时间变化:2019年aHR 1.67,2023年aHR 0.84;随访≥3年aHR 0.88。

核心结论

  • 社会处方触达了健康和社会需求更高的人群。
  • 随COVID-19后服务成熟和随访延长,社会处方与T2D风险降低相关,可能反映累积参与,但活动数据不可用。

研究设计与样本

  • 观察性研究,使用英格兰Oxford-RCGP研究与监测中心超过1800家全科诊所的常规数据(2019年1月至2023年11月)。
  • 横断面分析使用多变量logistic回归探讨高危T2D成人中社会处方转诊的相关因素。
  • 队列分析估计社会处方转诊与 incident T2D的关联,调整基线协变量,并使用日历期分层Cox模型和探索性时间-索引分析。

主要发现

  • 转诊更常见于女性(aOR 1.42, 95%CI 1.40-1.43)、更贫困地区居民(aOR 1.89, 95%CI 1.86-1.93)、当前吸烟者(aOR 1.71, 95%CI 1.68-1.73)、肥胖者(aOR 1.19, 95%CI 1.17-1.21)、抑郁/焦虑者(aOR 2.52, 95%CI 2.49-2.54)和多病患者(aOR 1.45, 95%CI 1.43-1.47)。
  • 按日历年,社会处方与T2D风险增加相关见于2019年(aHR 1.67, 95%CI 1.20-2.32),但到2023年变为保护性(aHR 0.84, 95%CI 0.79-0.89)。
  • 按随访时间,社会处方与转诊后0-2年内T2D风险增加相关(aHR 1.09, 95%CI 1.04-1.15),但≥3年后为保护性(aHR 0.88, 95%CI 0.80-0.97)。

临床怎么用

  • 在初级保健中,可考虑将社会处方作为高危T2D成人预防策略的一部分,尤其针对健康和社会需求较高的人群。
  • 社会处方对T2D的预防效果可能需要较长时间(≥3年)才能显现,短期随访可能观察到风险增加。
  • 应关注社会处方服务的成熟度和持续参与,以最大化潜在获益。

局限性

  • 活动数据不可用,无法评估参与程度对效果的影响。
  • 观察性设计不能排除残余混杂。
  • 研究期间涵盖COVID-19大流行,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Social prescribing has expanded rapidly in English primary care since 2019 to support the prevention and management of long-term conditions. However, evidence on its equity of access and effectiveness for type 2 diabetes (T2D) prevention is limited. AIM: To examine the reach, equity of access, and potential impact of social prescribing on T2D prevention among adults at high risk. DESIGN AND SETTING: Observational study using routinely collected data from the Oxford-RCGP Research and Surveillance Centre, including >1800 general practices in England (January 2019 to November 2023). METHOD: Cross-sectional analyses using multivariable logistic regression examined factors associated with social prescribing referral among adults at high risk of T2D. Cohort analyses estimated the association between social prescribing referral and incident T2D, adjusting for baseline covariates. Calendar-period-stratified Cox models were used to capture programme roll-out and COVID-19 changes. Exploratory time-since-index analyses tested if effects varied over time. RESULTS: Among 2 326 400 adults at high-risk of T2D, 271 582 (11.7%) developed T2D over a median 3.7 years (interquartile range [IQR] 1.44-4.83). Referrals to social prescribing increased 9.5-fold from 0.3% (n = 3897/1 479 172) in 2019-2020 to 2.5% (n = 47 883/1 917 187) in January-November 2023, and were more common among women (adjusted odds ratio (aOR) 1.42, 95% confidence interval [CI] = 1.40 to 1.43), those living in more deprived areas (aOR 1.89, 95% CI = 1.86 to 1.93), current smokers (aOR 1.71, 95% CI = 1.68 to 1.73), people with obesity (aOR 1.19, 95% CI = 1.17 to 1.21), depression/anxiety (aOR 2.52, 95% CI = 2.49 to 2.54), and multimorbidity (aOR 1.45, 95% CI = 1.43 to 1.47). By calendar year, social prescribing was associated with an increased risk of T2D in 2019 (adjusted hazard ratio [aHR] 1.67, 95% CI = 1.20 to 2.32) but became protective by 2023 (aHR 0.84, 95% CI = 0.79 to 0.89). By follow-up, social prescribing was associated with an increased risk of T2D within 0-2 years post-referral (aHR 1.09, 95% CI = 1.04 to 1.15) but was protective after ≥3 years (aHR 0.88, 95% CI = 0.80 to 0.97). CONCLUSION: Social prescribing reached those with greater health and social need. The protective association against T2D emerged as services matured post-COVID-19 and with longer follow-up, potentially reflecting cumulative engagement, although activity data were unavailable.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Calderón-Larrañaga S, Meza-Torres B, de Lusignan S, et al. Equity and impact of social prescribing in type 2 diabetes prevention: cross-sectional and cohort study using national primary care data. Br J Gen Pract. 2026. PMID: 42225389. doi:10.3399/BJGP.2025.0748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。